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Presentation of Case
A 69-year-old women smoker was referred to the nephrology 
clinic for assessment of hypertension and declining kidney 
function. At the time of referral, serum creatinine was 241 
μmol/L and office blood pressure was 191/100 mm Hg. Her 
general practitioner had already performed 24-hour ambulatory 
monitoring and found no evidence of a white coat component 
to the hypertension. The patient was taking 4 antihypertensive 
agents (nifedipine long acting 60 mg daily, candesartan 32 mg 
daily, bisoprolol 10 mg daily, and bendroflumethiazide 2.5 mg 
daily). Serum creatinine was 110 μmol/L when last recorded, 
1 year before referral. Physical examination was unremarkable 
with negative urinalysis for blood and protein.
E.L. Schiffrin: On the history, you have a smoker with 
impaired renal function and no proteinuria. I think this should 
evoke suspicions and I thought you should comment on it.
P.B. Mark: Absolutely. The diagnosis is clear that this is 
probably atherosclerotic renal artery disease. I don’t think 
there is any debate on this. If there had been proteinuria, it 
would have opened up the diagnosis to all kinds of glomeru-
lonephridities. We happened to have access to 1 test that day, 
the ultrasound test. That wouldn’t have been the ideal test to 
seal the diagnosis.
G.L. Jennings: Was there an abdominal bruit? And would 
you like to comment on the usefulness of abdominal bruit?
P.B. Mark: I remember examining this lady and there was 
not an abdominal bruit. I also listened for femoral bruit. She 
did not have an abdominal or femoral bruit.1
Renal ultrasound revealed asymmetrical kidneys with the 
left kidney measuring 8.1 cm with loss of cortical tissue. The 
right kidney measured 11 cm and appeared normal. The posi-
tive smoking history, renal impairment, resistant hyperten-
sion, and asymmetrical kidneys on ultrasound were highly 
suggestive of renovascular disease.
E.L. Schiffrin: You mentioned already renal artery stenosis, 
so I can ask whether you see atherosclerotic renal artery ste-
nosis, in the absence of smoking or diabetes mellitus or other 
causes of severe disseminated atherosclerosis?
P.B. Mark: I would say no in general, but I have just had 
a similar case referred to me, which I have yet to see. I think 
they may need more lipid work-up. It is surprising to see a 
40-year-old nonsmoker referred with atherosclerotic renal 
artery disease.
Her referring physician debated whether further imaging 
was likely to lead to alteration in management. The rapid 
decline in kidney function in the presence of a normal-sized 
right kidney with preserved cortical tissue gave rise to the 
possibility of remediable critical right renal artery stenosis. 
We considered magnetic resonance angiography, computed 
tomographic angiography, and formal invasive renal angiog-
raphy as imaging modalities for assessment of renal artery 
stenosis. Impaired renal function with estimated glomerular 
filtration rate 18 mL/min/1.73 m2 is a relative contraindica-
tion for magnetic resonance angiography, in light of the risk 
of nephrogenic systemic fibrosis.2 Therefore, computed tomo-
graphic angiography with prehydration was performed as first 
choice noninvasive imaging. Computed tomographic angiog-
raphy confirmed the presence of a tight calcific ostial stenosis 
of right renal artery (arrowed), as well as moderately heavy 
aortic calcification and an atrophic left kidney (Figure 1)
Intervention With Renal Artery Stenting  
and Outcome
On the basis of declining kidney function, with resistant 
hypertension, in the presence of a critical stenosis to a single 
functioning kidney, we elected to proceed to renal artery inter-
vention. The patient underwent renal artery CO2 angiography 
with right renal artery angioplasty and stenting without com-
plication (Figure 2).
For the subsequent days, there was a rapid normalization 
of renal function and substantial improvement in blood pres-
sure, with creatinine falling to 92 μmol/L at 9 months post 
procedure. When most recently seen at clinic, 18 months post 
procedure, office blood pressure was well controlled (148/88 
mm Hg) on 2 agents (bisoprolol and nifedipine) and serum 
creatinine was 122 μmol/L (estimated glomerular filtration 
rate 40 mL/min/1.73 m2).
The slight dip in renal function at 18 months post procedure 
suggests the possibility of late in-stent restenosis, although no 
repeat imaging has been performed to date.3 Even with this 
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minor dip, it is clear that this case represents successful short- 
to medium-term outcome with renal artery angioplasty plus 
stenting for atherosclerotic renal artery stenosis. We will con-
tinue to work hard with the patient to address her other risk 
factors for atherosclerosis, including smoking cessation, treat-
ment of dyslipidemia, and optimizing blood pressure control 
to try and protect the function of the single functioning kidney.
A.F. Dominiczak: Would you want to reimage and perhaps 
be ready to push the balloon across?
P.B. Mark: That is what we would like to do. However, the 
patient is extremely reluctant. And with the previous history 
of smoking and the several drugs, that is her choice. We would 
like to reimage. We had some debate with our radiologist 
because with the stent, we may have more difficulty imaging 
the stenosis and whether a straight angiogram might be better.
J.-G. Wang: You need to use ultrasound imaging to look at 
the change in the kidney and image the size of the kidney. That 
will tell us whether it is reversible or not reversible.
P.B. Mark: Yes, I think that is reasonable. If the kidney has 
become smaller or if the corticomedullary differentiation is 
less good, then it is possible to say that this may become less 
and less treatable.
E.L. Schiffrin: Have you succeeded in stopping her from 
smoking?
P.B. Mark: We have tried very, very hard. The answer is no. 
It makes you wonder about throwing all these treatments and 
exposing the patient to procedural risk as well.
Successful Result in the Context of Recent 
Clinical Trials
This successful result contrasts with recent well-conducted, 
high-profile randomized controlled trials of renal artery 
angioplasty and stenting compared with optimal medi-
cal therapy. The Angioplasty and Stenting for Renal Artery 
Lesions (ASTRAL),4 Cardiovascular Outcomes in Renal 
Atherosclerotic Lesions (CORAL),5 and Stent Placement and 
Blood Pressure and Lipid-Lowering for the Prevention of 
Progression of Renal Dysfunction Caused by Atherosclerotic 
Ostial Stenosis of the Renal Artery (STAR)6 trials have con-
sistently failed to show benefit with renal artery stenting 
compared with medical treatment, in terms of either patient 
survival, cardiovascular events, renal function, or blood pres-
sure. ASTRAL, which was a global study, including several 
patients in Glasgow, randomized 806 patients with uni- or 
bilateral atherosclerotic renal artery stenosis to stenting or 
medical therapy and showed no difference in blood pres-
sure, renal function, or progression to end-stage renal disease 
between the groups undergoing intervention compared with 
medical therapy. Renal artery stenting is not without risk, and 
in ASTRAL, serious adverse events directly related to renal 
revascularization were seen in 2.3% patients, including death 
and toe of limb amputation.4 The smaller STAR trial com-
pared renal artery stenting (64 patients) to medical therapy 
(76 patients) and showed no overall difference in progres-
sion of renal dysfunction between the groups.6 More recently, 
CORAL, in North America, randomized 947 patients with 
atherosclerotic renal artery stenosis and either hypertension 
or chronic kidney disease to renal artery stenting or medical 
therapy. For a median of 43 months follow-up, there was no 
difference in the composite end point of death from cardio-
vascular or renal causes, myocardial infarction, stroke, con-
gestive heart failure, progressive chronic kidney disease, or 
end-stage renal disease between the stented group and those 
treated with medical therapy.5
M. De Buyzere: Was she a good candidate to stent?
P.B. Mark: We had a good result. We have stented plenty 
over the years sometimes, with much poorer results. We would 
argue if ever there was a case for some benefit to be had, this 
was it. I do take your point. There was definitely established 
damage there, the renal function was poor, and the kidney was 
relatively small in size and there were other patient-related 
factors.
G.L. Jennings: As you just said, the results of the major 
trials in atherosclerotic renal artery stenosis have shown no 
benefit with the intervention over medical therapy. So that 
raises the question whether you went back a little bit further, 
would you really consider whether you should image her at 
all because medical therapy is what the guidelines are going 
to recommend.
This case demonstrates that there remains a group of patients 
who do benefit from stenting. Most clinicians accept that 
recurrent or flash pulmonary edema with preserved left ven-
tricular systolic function in patients with renal artery stenosis 
Figure 1. Computed tomographic renal angiography showing 
tight ostial right renal artery stenosis.
Figure 2. CO2 renal angiography confirms the presence of right 
renal artery stenosis before angioplasty and stenting.
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is an indication for renal angioplasty ± stenting.7 Renal revas-
cularization is unlikely to benefit patients with well-controlled 
blood pressure even on several agents and stable renal func-
tion. Small, shrunken kidneys have undergone irreversible 
ischemic damage, and functional improvement should not 
be anticipated with revascularization. Uncertainty remains in 
patients with renal artery disease and coexistent heart failure.8 
The patients enrolled in these admirable clinical trials cannot 
represent every clinical scenario, and it is inevitable that high-
risk patients, similar to the case presented, present particular 
diagnostics challenges and may not have been randomized in 
large numbers to these trials.9 Better characterization of the 
renal artery lesion using measures of fractional flow reserve 
may be helpful.10 Alternatively, functional assessment of the 
kidneys for hibernating renal tissue, which may benefit from 
revascularization, has been described.11 The results of these 
clinical trials should not deter clinicians from considering 
renal artery intervention, in carefully selected cases, where 
benefit is likely or the risks of stenting are outweighed by the 
likelihood of rapid progression to end-stage kidney disease in 
the absence of intervention.
Final Discussion of Hot Topics in Renal Artery 
Stenosis
A.F. Dominiczak: Can we go back to the picture with the nar-
rowing and closing renal artery? There is a tiny, tiny flow there 
and it is about to close. What would happen next if nothing 
had been done? Well, I have had an identical patient. This was 
my first patient in the blood pressure unit many years ago, and 
we published this paper with Professor Chris Isles. What hap-
pened to the patient next was that she became anuric, the same 
age; everything was similar. She had malignant hypertension. 
She completely relied on the tiny bit of 1 closing renal artery. 
So this is a tightening stenosis to a sole kidney and next is 
dialysis. It is easy to criticize, but clearly 2 years later, this 
patient still does not need renal replacement therapy. So some-
thing has been achieved.
A. Brady (Glasgow): We had a lot of patients from our series 
in ASTRAL. For people who don’t know how we recruited it; 
if a patient had a stenosis like this, they never went in the 
trial. They got angioplasty. For all the patients who had 50% 
to 60% stenosis, where you weren’t sure, they sort of got put 
in the trial. I can’t speak for CORAL, but I bet for the CORAL 
centers, which are mostly North American; those patients with 
really severe stenosis were never included in the studies. So 
those trials actually tell us nothing about critical stenosis, and 
I think for this individual there is clear benefit.
J. Dawson (Glasgow): I would support you. I would have 
referred that patient for stenting. If we were to go back in time, 
even with the trial data I would still refer that patient for stent-
ing. I think the more interesting question is what would I do 
now? Now that the renal function has declined. And the ques-
tion I have to help me make my mind up is: How much of the 
bounce in estimated glomerular filtration rate, the improve-
ment, and subsequent change was because of perioperative 
stopping of the angiotensin receptor blocker and perhaps 
restarting or was therapy the same the whole way through?
P.B. Mark: The therapy was not the same. I can’t answer 
the exact magnitude of each change, but the day post stenting, 
there was a drop in blood pressure. She had a torrential natri-
uresis and diuresis, blood pressure dropped, all drugs were 
stopped, then it was a labile evolving situation and it makes it 
extremely difficult to reinterpret what happened with the rein-
troduction of the drugs. But we didn’t reintroduce an angio-
tensin receptor blocker because there was no other compelling 
reason to do so. Although I think reintroducing any antihyper-
tensive drug will probably lead to a relative drop in the renal 
perfusion again. We don’t know what her actual baseline is.
G.L. Jennings: Just a comment on the people with really 
tight stenosis didn’t go into these trials, so we don’t really 
know. CORAL did a retrospective subgroup analysis; those 
with a stenosis over 80% didn’t show any different from those 
with a stenosis <80%. You probably need 80% for it to be 
functionally significant.
M. De Buyzere: For functional renal reserve, do you have 
a proposal for a cut-off where you should do it? For pressure-
wire for instance.
P.B. Mark: I don’t. For ASTRAL, I don’t recall the exact 
entry criteria, but it was ≈50% to 70%. It was a less severe ste-
nosis. We have no experience pressure-wiring. We have some 
experimental experience of doing magnetic resonance-perfu-
sion renography, which has been published by the Manchester 
group.12
 It does look impressive for predicting response to 
renal revascularization, but we don’t have a big enough case 
series of those. I think it comes back to the ultrasound actually. 
If they have a decent-size cortex and a reasonable-size kidney, 
there is a reasonable chance it might be a good outcome. If 
it’s a 9 cm kidney or below, it’s unlikely to be a good result. 
This was a 11 cm kidney, what if it had been a 10 cm kidney? 
I think it is difficult and that is where more data are required.
M. Walters (Glasgow): I am going to test Anna’s earlier 
assertion that there are no stupid questions. Now that the renal 
function is deteriorating 9 months after the stent was inserted, 
the question is whether it is instant restenosis or not. What is 
the role or is there a potential role for contrast-free imaging, 
using for instance time of flight magnetic resonance angiogra-
phy, which would obviate any risk of contrast-induced injury 
to the patient but may be sufficient to answer the specific ques-
tion about the presence or absence of in-stent restenosis?
P.B. Mark: I’m not sure that is a stupid question. That is way 
over my head. Seriously, I think that with magnetic resonance 
angiography, time of flight imaging is a beautiful concept. But 
the artifact with magnetic resonance imaging relating to the 
actual stent itself is going to make this difficult. I don’t have 
any experience with it.
J.A. Staessen: Why would you do the imaging again in this 
patient? Suppose you find out that the stent is thrombosed. 
What would you do?
P.B. Mark: I hope it is not thrombosed as the renal function 
would be considerably worse. I think that is an extremely difficult 
question to answer. If we find that there is a significant degree 
of in-stent restenosis, do we go back and subject the patient to 
another procedure and we will go round in the loop again?
E.L. Schiffrin: If we are spending so much money, or intend 
to, on this patient, why can’t we spend a lot of money on stop-
ping her from smoking? Surely, this has contributed to any 
additional vascular damage that has occurred since the recent 
intervention.
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J.-G. Wang: How often do you see this kind of patient? If 
you see rarely, 1 or 2 patients a year, I think that is not a prob-
lem. We also had a similar case as you had with a rapid renal 
function decline. The severity of stenosis is not a good indica-
tor, but rapid renal decline is a good indicator.
P.B. Mark: We don’t look hard for renal artery stenosis 
beyond the clinical diagnosis. In the post-ASTRAL and 
post-CORAL age, we don’t pursue renal artery stenting as 
aggressively as we did in the late 1990s and 2000s. I don’t 
think we perform >≈5 or 10 a year. We used to do many more 
than this.
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